FindTrial
Sign In

89Zr-Girentuximab

DIAGNOSTIC_TEST6 trials

Sponsors

Radboud University Medical Center, Telix Pharmaceuticals (Innovations) Pty Limited, South Metropolitan Health Service, Massachusetts General Hospital

Conditions

Carcinoma, Renal CellClear Cell Renal CarcinomaClear Cell Renal Cell CarcinomaClear Cell Renal Cell Carcinoma (ccRCC)Recurrent Renal Cell CancerSuspected Recurrent Renal Clear Cell CarcinomaUrothelial CarcinomaccRCC

Phase 1

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE
CompletedNCT03556046
Radboud University Medical CenterClear Cell Renal Carcinoma
Start: 2018-04-05End: 2018-12-17Updated: 2019-04-01
Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC
CompletedNCT04496089
Telix Pharmaceuticals (Innovations) Pty LimitedCarcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma
Start: 2020-08-01End: 2021-04-06Updated: 2021-08-24
Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients
CompletedNCT05046665
South Metropolitan Health ServiceUrothelial Carcinoma
Start: 2021-05-14End: 2022-08-09Updated: 2024-04-22
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
CompletedNCT05861778
Telix Pharmaceuticals (Innovations) Pty LimitedClear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Suspected Recurrent Renal Clear Cell Carcinoma
Start: 2023-06-26End: 2023-11-27Updated: 2023-12-11

Phase 2

CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
Not yet recruitingNCT07077083
Massachusetts General HospitalccRCC, Clear Cell Renal Cell Carcinoma (ccRCC)
Start: 2026-09-16End: 2028-08-01Target: 10Updated: 2026-07-21

Phase 3

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
CompletedNCT03849118
Telix Pharmaceuticals (Innovations) Pty LimitedClear Cell Renal Cell Carcinoma
Start: 2019-08-15End: 2022-11-07Updated: 2024-05-17

Related Papers

Evaluation of [89Zr]Zr-girentuximab PET imaging of clear cell renal cell carcinoma in Chinese patients: a Phase 1 clinical study (ZIRDOSE-CP)
EJNMMI Research2025-12-24
Radiation protection considerations with [89Zr]Zr-girentuximab PET and surgery
EJNMMI Research2025-05-23
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.
2024-09-1059 citations
<sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study.
Journal of Clinical Oncology2023-06-019 citations
LBA03-01  <sup>89</sup> Zr-DFO-GIRENTUXIMAB FOR PET/CT IMAGING OF INDETERMINATE RENAL MASSES–RESULTS FROM PHASE 3 ZIRCON STUDY
The Journal of Urology2023-03-23
Results from phase 3 study of <sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).
Journal of Clinical Oncology2023-02-2036 citations
<sup>89</sup>Zirconium-labelled girentuximab (<sup>89</sup>Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma.
Journal of Clinical Oncology2022-06-01
<sup>89</sup> Zirconium-labelled girentuximab ( <sup>89</sup> Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
BMJ Open2022-04-0114 citations
Phase I study to assess safety, biodistribution and radiation dosimetry for <sup>89</sup>Zr-girentuximab in patients with renal cell carcinoma.
2021-03-0241 citations